Part 54's financial disclosure is a per-investigator test

A covered study, not every study a sponsor runs

21 CFR 54.2 defines a covered clinical study narrowly: a study of a drug or device in humans, submitted in a marketing application or reclassification petition, that the applicant or FDA relies on to establish effectiveness — including a study relied on to show equivalence to an already-effective product — or a study in which a single investigator makes a significant contribution to the demonstration of safety. Early feasibility work nobody is relying on for either finding sits outside that definition. The moment a study becomes one FDA or the applicant actually leans on to make the safety or effectiveness case, though, Part 54's disclosure duty attaches to it, and the duty then runs to a broader set of people than the sponsor's own org chart might suggest: the regulation's own definition of a clinical investigator reaches every listed or identified investigator and sub-investigator directly involved in treating or evaluating subjects, along with that person's spouse and each dependent child.

Three interest categories, each triggered on its own terms

54.2 names three kinds of disclosable financial interest, and none of them requires the other two to be present. A proprietary interest in the tested product — a patent, a trademark, a copyright, or a licensing agreement covering it — counts regardless of dollar value; there's no minimum stake that has to be crossed. A significant equity interest reaches any ownership stake, stock option, or other interest in a nonpublicly traded sponsor whose value can't be readily determined by reference to a public price, or, for a publicly traded sponsor, an equity interest exceeding $50,000 held during the study and for one year after it ends. Significant payments of other sorts — consulting fees, honoraria, grants supporting the investigator's own activities — count once they exceed $25,000 from the study's sponsor, not counting whatever the sponsor paid to actually run the trial itself. An investigator can clear two of the three categories and still owe disclosure on the third; the test runs independently on each one, for each investigator, not as a combined score.

Certify or disclose — there's no third form

Once the covered-study question is settled, the applicant's own filing duty is binary for each investigator on the list: either certify that no disclosable financial interest exists, on Form FDA 3454, or disclose whatever interest does exist, on Form FDA 3455, along with a description of what steps were taken to reduce the potential for bias — a larger and more geographically distributed subject pool, blinding, an independent statistical analysis, or additional monitoring beyond what the study would otherwise carry. Nothing about a study's overall design forces one form for the whole investigator list. A sponsor-investigator, this blog has already covered, owes a sponsor's full duties and an investigator's full duties on top of each other, never a blended version of either — and that same person's own financial interests still get tested against 54.2 in the investigator role, independent of whatever sponsor-side obligations that same signature also carries.

A disclosed interest doesn't sink the data; a missing form does

Crossing one of the three thresholds isn't, by itself, a reason FDA rejects an investigator's results. The disclosure and the bias-mitigation description are what let the data still count toward the application — the point of Part 54 is transparency the agency can weigh, not an automatic disqualification. What actually stops a PMA at the filing gate, this blog has already covered, is a presence-or-absence question: whether the certification or disclosure statement Part 54 requires is attached to the application at all. An applicant that ran the per-investigator test correctly and just forgot to attach the resulting form loses just as much time at that gate as one that never ran the test to begin with.

Where this meets the file

A financial-disclosure tracker needs one row per listed investigator, not one line for the study: which of the three 54.2 categories was checked, what was found, and whether the resulting filing is a 3454 certification or a 3455 disclosure with its bias-mitigation description attached. A per-investigator financial-disclosure worksheet built around that structure is previewed in the launch catalog. If your program tracks this differently, the shelf takes that correction directly.